Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis
Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment
consisting of perioperative combination chemotherapy with the vascular endothelial growth
factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.